Letter to editor – a response to: ‘efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review’

Click to increase image sizeClick to decrease image size

Acknowledgments

D Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). Editorial support (in the form of collating author comments, grammatical editing and referencing) was provided by Chrystelle Rasamison, at Fishawack Indicia Ltd, part of Fishawack Health, and was funded by GlaxoSmithKline (GSK).

Declaration of interest

NC Barnes, P Jones, and DA Lipson are employees of GSK and hold stocks and shares in GSK. D. Singh has received personal fees from GSK, Cipla, Genentech and Peptinnovate, and personal fees and grant support from AstraZeneca, Boehringer Ingelheim, Chiesi, Glenmark, Menarini, Mundipharma, Novartis, Pfizer, Pulmatrix, Theravance and Verona. FJ Martinez has received personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Inova Fairfax Health System, Methodist Hospital, National Society for Continuing Education/Haymarket, Novartis, Pearl Pharmaceuticals, PeerView Communications, Physicians Education Resource, Chiesi, CSL Behring, Sunovion, University of Alabama Birmingham, Physicians Education Resource, Canadian Respiratory Network, CME Outfitters, Teva, Vindico and Dartmouth, non-financial support from Bioscale/ProterrixBio, Nitto and Zambon, personal fees from MD Magazine, New York University, UpToDate, WebMD/MedScape, Patara/Respivant, Rockpointe, Rare Disease Healthcare Communications, France Foundation and Prime Education and other support from AstraZeneca (non-personal travel support; academic co-authorship), Boehringer Ingelheim (steering committee; non-personal travel support), Bioscale/ProterrixBio (advisory board attendance with no direct financial compensation), Afferent/Merck (IPF Steering Committee), Gilead Sciences (co-authorship on IPF Study Steering Committee), Patara/Respivant (IPF Steering Committee), Stromedix/Biogen, Veracyte (co-authorship on IPF Study Steering Committee), Prometic (IPF Steering Committee), Bayer (ILD Steering Committee), Bridge Biotherapeutics (IPF consultation), Bristol-Myers Squibb (IPF consultation), Physicians Education Resource (IPF Advisory Board), ProMedior/Roche (IPF Steering Committee), twoXR (IPF Teleconsulation), and Gala (Advisory Board attendance). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

The IMPACT trial was funded by GSK (study CTT116855; NCT02164513).